Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pragmatic Clinical Trial of Fufei Huazhuo Tongluo Formula Combined With Standardized Western Medicine for Glucocorticoid-Sparing Efficacy in Patients With Anti-Synthetase Syndrome-Associated Interstitial Lung Disease

NCT07836790 is registered in ClinicalTrials.gov with First People's Hospital of Hangzhou as lead sponsor.

NCT NCT07836790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07836790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pragmatic Clinical Trial of Fufei Huazhuo Tongluo Formula Combined With Standardized Western Medicine for Glucocorticoid-Sparing Efficacy in Patients With Anti-Synthetase Syndrome-Associated Interstitial Lung Disease
Lead sponsor
First People's Hospital of Hangzhou
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 10, 2026
Completion date
December 31, 2028
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-synthetase syndrome, interstitial lung disease (ild)